The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

Gill H, Yacoub A, Gerds AT, Shortt J, Rossetti JM, Mead AJ, Göthert JR, Koschmieder S, Ewing J, Halpern AB, Palandri F, Passamonti F, Mesa R, Marchetti M, Harrison C, Vannucchi AM, Watts JM, Wood JC, Ross DM, Peppe J, Natsoulis G, Rienhoff HY Jr

Open source

DOI: 10.1182/bloodadvances.2025018141
Published: 2026 Jul 14
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2025018141,
  title = {The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.},
  author = {Gill H and Yacoub A and Gerds AT and Shortt J and Rossetti JM and Mead AJ and Göthert JR and Koschmieder S and Ewing J and Halpern AB and Palandri F and Passamonti F and Mesa R and Marchetti M and Harrison C and Vannucchi AM and Watts JM and Wood JC and Ross DM and Peppe J and Natsoulis G and Rienhoff HY Jr},
  year = {2026},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2025018141},
  url = {https://doi.org/10.1182/bloodadvances.2025018141}
}

RIS

TY  - JOUR
TI  - The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.
AU  - Gill H
AU  - Yacoub A
AU  - Gerds AT
AU  - Shortt J
AU  - Rossetti JM
AU  - Mead AJ
AU  - Göthert JR
AU  - Koschmieder S
AU  - Ewing J
AU  - Halpern AB
AU  - Palandri F
AU  - Passamonti F
AU  - Mesa R
AU  - Marchetti M
AU  - Harrison C
AU  - Vannucchi AM
AU  - Watts JM
AU  - Wood JC
AU  - Ross DM
AU  - Peppe J
AU  - Natsoulis G
AU  - Rienhoff HY Jr
PY  - 2026
JO  - Blood advances
DO  - 10.1182/bloodadvances.2025018141
UR  - https://doi.org/10.1182/bloodadvances.2025018141
ER  -

APA

H, G., A, Y., AT, G., J, S., JM, R., AJ, M., JR, G., S, K., J, E., AB, H., F, P., F, P., R, M., M, M., C, H., AM, V., JM, W., JC, W., DM, R., J, P., G, N., & Jr, R. H. (2026). The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.. Blood advances. https://doi.org/10.1182/bloodadvances.2025018141

Source records

pubmed · retrieved 2026-09-26T18:03:42.540Z